Protara Therapeutics (TARA) Payables (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Payables data on file, last reported at $4.0 million in Q1 2026.

• On a quarterly basis, Payables rose 74.5% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 74.5% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, down 21.7% from the prior year.
• Payables for Q1 2026 stood at $4.0 million, up from $3.5 million in the prior quarter.
• Over the last five years, Payables for TARA reached as high as $5.3 million in Q2 2025 and fell as low as $392000.0 in Q2 2022.
• Historically, Payables has averaged $2.5 million across 5 years, with a median of $2.3 million in 2025.
• Across the five-year window, Payables surged 654.34% in 2023 and tumbled 76.18% in 2024, its largest moves.
• Year by year, Payables stood at $1.6 million in 2022, then jumped by 53.47% to $2.4 million in 2023, then jumped by 81.96% to $4.4 million in 2024, then slipped by 21.7% to $3.5 million in 2025, then rose by 16.23% to $4.0 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $4.0 million in Q1 2026, $3.5 million in Q4 2025, and $4.5 million in Q3 2025.